Showing 2761-2770 of 5771 results for "".
- PolyActiva Appoints Jerry St. Peter as CEO; Secures Financing to Advance Prezia Technology Platformhttps://modernod.com/news/polyactiva-appoints-jerry-st-peter-as-ceo-secures-financing-to-advance-prezia-technology-platform/2482854/PolyActiva announced two milestones in its next phase of growth: the appointment of biopharmaceutical executive Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund
- Johnson & Johnson Launches Tecnis Odyssey IOL in Europe, the Middle East, and Canadahttps://modernod.com/news/johnson-johnson-launches-tecnis-odyssey-iol-in-europe-the-middle-east-and-canada/2482853/Johnson & Johnson announced that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of Tecnis Odyssey IOL in Europe, the Middle East, and Canada. According to J&J, the new full visual range IOL offers high-quality and c
- Amaros Expands Advisory Board; Closes Series A Financinghttps://modernod.com/news/amaros-expands-advisory-board-closes-series-a-financing/2482852/Amaros announced the successful close of its Series A financing and the formation of an advisory board. Backed by a group of new and existing investors, Amaros said the Series A funding will f
- Aldeyra Resubmits Reproxalap NDA for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aldeyra-resubmits-reproxalap-nda-for-the-treatment-of-dry-eye-disease/2482851/Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease. Per FDA agreement
- Sightview Appoints Tycene Fritcher as CEOhttps://modernod.com/news/sightview-appoints-tycene-fritcher-as-ceo/2482850/Ophthalmic Electronic health record (EHR) provider Sightview announced that Tycene Fritcher has been appointed Chief Executive Officer. Ms. Fritcher brings more than two decades of leadership experience in healthcare IT, including tenures at Nextech, Avizia, and Am
- Heidelberg Engineering Launches ZinserLab Innovation Hub to Accelerate Imaging Innovation in Eye Carehttps://modernod.com/news/heidelberg-engineering-launches-zinserlab-innovation-hub-to-accelerate-imaging-innovation-in-eye-care/2482848/Heidelberg Engineering announced the launch of the ZinserLab, an innovation hub that aims to accelerate the development of imaging technologies with clinical value for eye care. The hub is named in honor of Dr. Gerhard Zinser, the
- Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic Suspensionhttps://modernod.com/news/amneal-receives-fda-approval-for-prednisolone-acetate-ophthalmic-suspension/2482847/Amneal Pharmaceuticals announced the FDA approval of prednisolone acetate ophthalmic suspension 1% sterile, which references Pred Forte (Allergan, an AbbVie company). Launch of the product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension USP 1% i
- Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Datahttps://modernod.com/news/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data/2482846/Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a
- SpliceBio Secures $135M Series B to Advance Gene Therapy for Stargardt Diseasehttps://modernod.com/news/splicebio-secures-135m-series-b-to-advance-gene-therapy-for-stargardt-disease/2482845/SpliceBio announced the closing of a $135 million Series B financing round to support the clinical advancement of SpliceBio’s lead gene therapy candidate, SB-007, for Stargardt disease. There are currently no approved treatments for the disease, which is
- Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucomahttps://modernod.com/news/qlaris-bio-developing-fixed-dose-combination-therapy-for-the-treatment-of-glaucoma/2482844/Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for p